<DOC>
	<DOC>NCT01040325</DOC>
	<brief_summary>The purpose of this study is to evaluate the efficacy of the TD Vaccine System to prevent moderate to severe enterotoxin E.coli (ETEC) disease in travelers to India.</brief_summary>
	<brief_title>Traveler's Diarrhea (TD) Vaccine Asia Efficacy Study</brief_title>
	<detailed_description />
	<mesh_term>Diarrhea</mesh_term>
	<mesh_term>Dysentery</mesh_term>
	<mesh_term>Vaccines</mesh_term>
	<criteria>1864 years of age at date of first vaccination Good health as determined by medical history and physical inspection Females of childbearing potential must have a negative pregnancy test prior to first and second vaccination in the country of origin; females of childbearing potential must agree not to become pregnant throughout the duration of study Subjects must have planned travel to DC, within 3 hours traveling distance of approved study site(s), for a minimum duration of stay of 7 days (no maximum stay is specified for inclusion). Subject must be able to communicate in English Abnormalities as determined by the Investigator/clinician during physical inspection; Participated in research involving investigational product within 30 days before planned date of first vaccination; Ever received LT, ETEC, or cholera vaccine; History of diarrhea while traveling in a developing country within the last year; Women who are pregnant or breastfeeding; Clinically significant underlying enteric, pulmonary, cardiac, liver or renal disease; History of Irritable Bowel Syndrome; Seizure disorder within the last year; Current use of immunosuppressive therapy (excluding inhaled steroids) or immunodeficiency; Known or suspected alcohol abuse or illicit drug use within the last year; Medical history of HIV, HBV, or HCV; An employee of a study site; Known allergies to any component of the vaccine, including adhesives; Planned use of antibiotics with known activity against gram negative facultative anaerobes; Planned use of antacids, antidiarrheals, loperamide, bismuth subsalicylate, diphenoxylate or similar from two weeks prior to randomization through the surveillance phase of the study; An employee of Intercell (global) or an immediate family member.</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>64 Years</maximum_age>
	<verification_date>January 2012</verification_date>
</DOC>